Xavier RCMI Center for Cancer Research

泽维尔 RCMI 癌症研究中心

• 批准号: 8740738
• 负责人: Gene D'Amour
• 金额: $ 238.65万
• 依托单位: XAVIER UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-24 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8740738
• 关键词: African American; Area; Binding; Bioinformatics; Biological Sciences; Biomedical Research; Caucasians; Caucasoid Race; Cellular biology; Center for Translational Science Activities; Cessation of life; Clinical Sciences; Collaborations; Commit; Communities; Core Facility; Data Collection; Development; Disease; Drug Delivery Systems; Drug Design; Faculty; Funding; Goals; Grant; Growth; Health; Health Sciences; Individual; Institution; Investments; Knowledge; Laboratories; Lead; Louisiana; Malignant Neoplasms; Measurable; Medical; Mentors; Minority; Molecular Biology; NCI Center for Cancer Research; Outcome; Peer Review; Pharmacists; Pilot Projects; Population; Process; Productivity; Program Development; Public Health; Recording of previous events; Research; Research Personnel; Research Project Grants; Research Support; Resources; Science, Technology, Engineering and Mathematics; Scientist; Series; Services; Source; Strategic Planning; Structure; Support System; Technology Transfer; Time; Training; Translating; Translational Research; United States National Institutes of Health; Universities; Vision; Work; anticancer research; cancer health disparity; driving force; drug discovery; health disparity; improved; innovation; meetings; minority health; programs; public health relevance; tool

DESCRIPTION (provided by applicant): Since its inception in 2009, Xavier University's RCIVII Center for Cancer Research has been a driving force toward achieving the University's goal of becoming a national leader in cancer and health disparities research. We propose five alms in order to move closer to attaining this goal. (1) Strengthen internal and external collaborations and partnerships, particularly those that promote health disparities and translational research: building on existing collaborations with LSU, LSU Health Sciences Center, Tulane University and the Pennington Biomedical Research Center through active partnerships in the Louisiana Cancer Research Consortium and the Louisiana Biomedical Research Network, we will leverage research and mentoring resources in place and establish new ones via partnerships formed within Xavier and between Xavier and RTRN institutions. (2) Reorganize and enhance critical core facilities: we will down size one existing core, create a new core in drug discovery and delivery and add -a bioinformatics facility to our existing Cell and Molecular Biology Core. (3) Increase Xavier's pool of competitive and productive cancer and health disparities researchers who participate in the translational research "pipeline:" we will retain previously hired, now competitive, RCMI faculty, hire additional promising junior faculty in critical "gap" areas that will improve our capabilities in health disparities and translational research, and provide these faculty with the resources necessary to become/remain competitive. (4)Establish a new pilot project program for cancer/health disparities research: we will use a peer-reviewed mechanism to select projects that will increase Xavier NIH R01 and other R-series grants and support pilot translational research projects for preliminary data collection. (5) Provide targeted administrative services in support of RCMI investigators: we will assure that faculty needs are met with minimal burden, research programs and core services are integrated and encourage teamwork, and that faculty development programs promote professional growth and engagement in health disparities and translational research. Successfully completing these aims will be significant because it will increase the pool of researchers who can more quickly translate bench discoveries into public benefit, particularly in minority communities. The research projects supported by the present RCMI proposal will be innovative as we propose to utilize a programmatic structure involving partnerships with major research universities, an NIH-supported Center for Minority Health and Health Disparities and an NIH-funded center for translational sciences.

描述（由申请人提供）：自2009年成立以来，泽维尔大学的RCIVII癌症研究中心一直是实现该大学成为癌症和健康差异研究国家领导者的目标的推动力。我们提出五项施舍，以便更接近实现这一目标。(1)加强内部和外部合作与伙伴关系，特别是那些促进健康差距和转化研究的合作与伙伴关系：通过路易斯安那州癌症研究联盟和路易斯安那州生物医学研究网络的积极合作，在与路易斯安那州立大学、路易斯安那州立大学健康科学中心、杜兰大学和彭宁顿生物医学研究中心的现有合作基础上，我们将充分利用现有的研究和指导资源，并通过泽维尔内部以及泽维尔与RTRN机构之间的合作关系建立新的资源。(2)重组和加强关键的核心设施：我们将缩小现有核心的规模，在药物发现和交付方面创建一个新的核心，并在现有的细胞和分子生物学核心中增加一个生物信息学设施。(3)增加泽维尔的竞争力和生产力的癌症和健康差异的研究人员谁参与转化研究“管道”的池：我们将保留以前聘请，现在竞争力，RCMI教师，聘请额外的有前途的初级教师在关键的“差距”领域，这将提高我们在健康差异和转化研究的能力，并为这些教师提供必要的资源，成为/保持竞争力。（4）建立一个新的癌症/健康差异研究试点项目计划：我们将使用同行评审机制来选择项目，这些项目将增加Xavier NIH R 01和其他R系列赠款，并支持试点转化研究项目进行初步数据收集。(5)提供有针对性 支持RCMI研究人员的行政服务：我们将确保教师的需求得到满足，负担最小，研究计划和核心服务是一体化的，并鼓励团队合作，教师发展计划促进专业成长和参与健康差异和转化研究。成功完成这些目标将具有重要意义，因为这将增加能够更快地将实验室发现转化为公共利益的研究人员，特别是在少数民族社区。本RCMI提案支持的研究项目将具有创新性，因为我们建议利用涉及与主要研究型大学，NIH支持的少数民族健康和健康差异中心以及NIH资助的转化科学中心合作的方案结构。